nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A7—Temsirolimus—kidney cancer	0.0989	0.128	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0989	0.128	CbGbCtD
Ethosuximide—CYP3A5—Temsirolimus—kidney cancer	0.0742	0.0963	CbGbCtD
Ethosuximide—CYP3A4—Everolimus—kidney cancer	0.0428	0.0556	CbGbCtD
Ethosuximide—CYP3A7—Paclitaxel—kidney cancer	0.034	0.0441	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.034	0.0441	CbGbCtD
Ethosuximide—CYP3A7—Sorafenib—kidney cancer	0.0302	0.0391	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0302	0.0391	CbGbCtD
Ethosuximide—CYP3A7—Vincristine—kidney cancer	0.0293	0.038	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0293	0.038	CbGbCtD
Ethosuximide—CYP3A4—Temsirolimus—kidney cancer	0.0289	0.0376	CbGbCtD
Ethosuximide—CYP3A5—Erlotinib—kidney cancer	0.0278	0.0361	CbGbCtD
Ethosuximide—CYP3A5—Paclitaxel—kidney cancer	0.0255	0.0331	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0244	0.0317	CbGbCtD
Ethosuximide—CYP3A7—Sunitinib—kidney cancer	0.0244	0.0317	CbGbCtD
Ethosuximide—CYP3A5—Sorafenib—kidney cancer	0.0226	0.0294	CbGbCtD
Ethosuximide—CYP3A5—Vincristine—kidney cancer	0.022	0.0285	CbGbCtD
Ethosuximide—CYP3A5—Sunitinib—kidney cancer	0.0183	0.0238	CbGbCtD
Ethosuximide—CYP3A4—Pazopanib—kidney cancer	0.0152	0.0197	CbGbCtD
Ethosuximide—CYP3A4—Erlotinib—kidney cancer	0.0108	0.0141	CbGbCtD
Ethosuximide—CYP3A4—Paclitaxel—kidney cancer	0.00993	0.0129	CbGbCtD
Ethosuximide—CYP3A4—Sorafenib—kidney cancer	0.00882	0.0114	CbGbCtD
Ethosuximide—CYP3A4—Vinblastine—kidney cancer	0.00871	0.0113	CbGbCtD
Ethosuximide—CYP3A4—Vincristine—kidney cancer	0.00856	0.0111	CbGbCtD
Ethosuximide—CYP3A4—Sunitinib—kidney cancer	0.00715	0.00928	CbGbCtD
Ethosuximide—CYP3A4—Doxorubicin—kidney cancer	0.00535	0.00695	CbGbCtD
Ethosuximide—Mental disorder—Vincristine—kidney cancer	0.000372	0.00197	CcSEcCtD
Ethosuximide—Decreased appetite—Everolimus—kidney cancer	0.000371	0.00197	CcSEcCtD
Ethosuximide—Leukopenia—Dactinomycin—kidney cancer	0.00037	0.00197	CcSEcCtD
Ethosuximide—Diarrhoea—Pazopanib—kidney cancer	0.00037	0.00196	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000369	0.00196	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Everolimus—kidney cancer	0.000368	0.00196	CcSEcCtD
Ethosuximide—Fatigue—Everolimus—kidney cancer	0.000368	0.00195	CcSEcCtD
Ethosuximide—Abdominal pain upper—Capecitabine—kidney cancer	0.000365	0.00194	CcSEcCtD
Ethosuximide—Vomiting—Temsirolimus—kidney cancer	0.000365	0.00194	CcSEcCtD
Ethosuximide—Immune system disorder—Gemcitabine—kidney cancer	0.000363	0.00193	CcSEcCtD
Ethosuximide—Nervous system disorder—Sorafenib—kidney cancer	0.000363	0.00193	CcSEcCtD
Ethosuximide—Mediastinal disorder—Gemcitabine—kidney cancer	0.000363	0.00193	CcSEcCtD
Ethosuximide—Rash—Temsirolimus—kidney cancer	0.000362	0.00192	CcSEcCtD
Ethosuximide—Dermatitis—Temsirolimus—kidney cancer	0.000361	0.00192	CcSEcCtD
Ethosuximide—Breast disorder—Capecitabine—kidney cancer	0.000361	0.00192	CcSEcCtD
Ethosuximide—Skin disorder—Sorafenib—kidney cancer	0.00036	0.00191	CcSEcCtD
Ethosuximide—Headache—Temsirolimus—kidney cancer	0.000359	0.00191	CcSEcCtD
Ethosuximide—Haematuria—Paclitaxel—kidney cancer	0.000358	0.0019	CcSEcCtD
Ethosuximide—Decreased appetite—Erlotinib—kidney cancer	0.000358	0.0019	CcSEcCtD
Ethosuximide—Dizziness—Pazopanib—kidney cancer	0.000357	0.0019	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000355	0.00189	CcSEcCtD
Ethosuximide—Hiccups—Doxorubicin—kidney cancer	0.000355	0.00189	CcSEcCtD
Ethosuximide—Fatigue—Erlotinib—kidney cancer	0.000355	0.00189	CcSEcCtD
Ethosuximide—Anorexia—Sorafenib—kidney cancer	0.000353	0.00188	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Vinblastine—kidney cancer	0.00035	0.00186	CcSEcCtD
Ethosuximide—Nervous system disorder—Sunitinib—kidney cancer	0.000349	0.00186	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Everolimus—kidney cancer	0.000349	0.00185	CcSEcCtD
Ethosuximide—Skin disorder—Sunitinib—kidney cancer	0.000346	0.00184	CcSEcCtD
Ethosuximide—Vomiting—Pazopanib—kidney cancer	0.000344	0.00182	CcSEcCtD
Ethosuximide—Rash—Pazopanib—kidney cancer	0.000341	0.00181	CcSEcCtD
Ethosuximide—Nausea—Temsirolimus—kidney cancer	0.000341	0.00181	CcSEcCtD
Ethosuximide—Dermatitis—Pazopanib—kidney cancer	0.00034	0.00181	CcSEcCtD
Ethosuximide—Anorexia—Sunitinib—kidney cancer	0.00034	0.0018	CcSEcCtD
Ethosuximide—Agitation—Vincristine—kidney cancer	0.000339	0.0018	CcSEcCtD
Ethosuximide—Abdominal pain—Vinblastine—kidney cancer	0.000339	0.0018	CcSEcCtD
Ethosuximide—Headache—Pazopanib—kidney cancer	0.000338	0.0018	CcSEcCtD
Ethosuximide—Abdominal pain—Everolimus—kidney cancer	0.000337	0.00179	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Erlotinib—kidney cancer	0.000337	0.00179	CcSEcCtD
Ethosuximide—Aplastic anaemia—Doxorubicin—kidney cancer	0.000333	0.00177	CcSEcCtD
Ethosuximide—Urinary tract disorder—Paclitaxel—kidney cancer	0.000333	0.00177	CcSEcCtD
Ethosuximide—Abdominal discomfort—Capecitabine—kidney cancer	0.000331	0.00176	CcSEcCtD
Ethosuximide—Connective tissue disorder—Paclitaxel—kidney cancer	0.000331	0.00176	CcSEcCtD
Ethosuximide—Leukopenia—Vincristine—kidney cancer	0.000331	0.00176	CcSEcCtD
Ethosuximide—Urethral disorder—Paclitaxel—kidney cancer	0.00033	0.00175	CcSEcCtD
Ethosuximide—Pancytopenia—Capecitabine—kidney cancer	0.000328	0.00174	CcSEcCtD
Ethosuximide—Abdominal pain—Erlotinib—kidney cancer	0.000325	0.00173	CcSEcCtD
Ethosuximide—Decreased appetite—Sorafenib—kidney cancer	0.000322	0.00171	CcSEcCtD
Ethosuximide—Anorexia—Dactinomycin—kidney cancer	0.000322	0.00171	CcSEcCtD
Ethosuximide—Nausea—Pazopanib—kidney cancer	0.000321	0.0017	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00032	0.0017	CcSEcCtD
Ethosuximide—Fatigue—Sorafenib—kidney cancer	0.000319	0.0017	CcSEcCtD
Ethosuximide—Erythema multiforme—Paclitaxel—kidney cancer	0.000319	0.00169	CcSEcCtD
Ethosuximide—Hypersensitivity—Vinblastine—kidney cancer	0.000315	0.00168	CcSEcCtD
Ethosuximide—Eye disorder—Paclitaxel—kidney cancer	0.000315	0.00167	CcSEcCtD
Ethosuximide—Hypersensitivity—Everolimus—kidney cancer	0.000314	0.00167	CcSEcCtD
Ethosuximide—Leukopenia—Gemcitabine—kidney cancer	0.000314	0.00167	CcSEcCtD
Ethosuximide—Weight decreased—Capecitabine—kidney cancer	0.000313	0.00166	CcSEcCtD
Ethosuximide—Decreased appetite—Sunitinib—kidney cancer	0.00031	0.00165	CcSEcCtD
Ethosuximide—Mental disability—Doxorubicin—kidney cancer	0.000308	0.00164	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000308	0.00163	CcSEcCtD
Ethosuximide—Asthenia—Vinblastine—kidney cancer	0.000307	0.00163	CcSEcCtD
Ethosuximide—Fatigue—Sunitinib—kidney cancer	0.000307	0.00163	CcSEcCtD
Ethosuximide—Asthenia—Everolimus—kidney cancer	0.000306	0.00163	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000305	0.00162	CcSEcCtD
Ethosuximide—Immune system disorder—Paclitaxel—kidney cancer	0.000304	0.00162	CcSEcCtD
Ethosuximide—Mediastinal disorder—Paclitaxel—kidney cancer	0.000304	0.00161	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Sorafenib—kidney cancer	0.000303	0.00161	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000296	0.00157	CcSEcCtD
Ethosuximide—Nervous system disorder—Vincristine—kidney cancer	0.000296	0.00157	CcSEcCtD
Ethosuximide—Asthenia—Erlotinib—kidney cancer	0.000295	0.00157	CcSEcCtD
Ethosuximide—Mental disorder—Paclitaxel—kidney cancer	0.000295	0.00157	CcSEcCtD
Ethosuximide—Urticaria—Sorafenib—kidney cancer	0.000294	0.00156	CcSEcCtD
Ethosuximide—Haematuria—Capecitabine—kidney cancer	0.000294	0.00156	CcSEcCtD
Ethosuximide—Malnutrition—Paclitaxel—kidney cancer	0.000293	0.00156	CcSEcCtD
Ethosuximide—Decreased appetite—Dactinomycin—kidney cancer	0.000293	0.00156	CcSEcCtD
Ethosuximide—Diarrhoea—Vinblastine—kidney cancer	0.000293	0.00156	CcSEcCtD
Ethosuximide—Abdominal pain—Sorafenib—kidney cancer	0.000293	0.00156	CcSEcCtD
Ethosuximide—Diarrhoea—Everolimus—kidney cancer	0.000292	0.00155	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Sunitinib—kidney cancer	0.000291	0.00155	CcSEcCtD
Ethosuximide—Fatigue—Dactinomycin—kidney cancer	0.000291	0.00154	CcSEcCtD
Ethosuximide—Agranulocytosis—Capecitabine—kidney cancer	0.000287	0.00153	CcSEcCtD
Ethosuximide—Anorexia—Vincristine—kidney cancer	0.000287	0.00153	CcSEcCtD
Ethosuximide—Dizziness—Vinblastine—kidney cancer	0.000283	0.0015	CcSEcCtD
Ethosuximide—Dizziness—Everolimus—kidney cancer	0.000282	0.0015	CcSEcCtD
Ethosuximide—Muscle spasms—Paclitaxel—kidney cancer	0.000282	0.0015	CcSEcCtD
Ethosuximide—Abdominal pain—Sunitinib—kidney cancer	0.000282	0.0015	CcSEcCtD
Ethosuximide—Diarrhoea—Erlotinib—kidney cancer	0.000282	0.0015	CcSEcCtD
Ethosuximide—Nervous system disorder—Gemcitabine—kidney cancer	0.00028	0.00149	CcSEcCtD
Ethosuximide—Skin disorder—Gemcitabine—kidney cancer	0.000278	0.00148	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000276	0.00147	CcSEcCtD
Ethosuximide—Urinary tract disorder—Capecitabine—kidney cancer	0.000273	0.00145	CcSEcCtD
Ethosuximide—Hypersensitivity—Sorafenib—kidney cancer	0.000273	0.00145	CcSEcCtD
Ethosuximide—Anorexia—Gemcitabine—kidney cancer	0.000273	0.00145	CcSEcCtD
Ethosuximide—Vomiting—Vinblastine—kidney cancer	0.000272	0.00145	CcSEcCtD
Ethosuximide—Dizziness—Erlotinib—kidney cancer	0.000272	0.00145	CcSEcCtD
Ethosuximide—Connective tissue disorder—Capecitabine—kidney cancer	0.000272	0.00144	CcSEcCtD
Ethosuximide—Vomiting—Everolimus—kidney cancer	0.000271	0.00144	CcSEcCtD
Ethosuximide—Urethral disorder—Capecitabine—kidney cancer	0.000271	0.00144	CcSEcCtD
Ethosuximide—Agitation—Paclitaxel—kidney cancer	0.00027	0.00143	CcSEcCtD
Ethosuximide—Rash—Everolimus—kidney cancer	0.000269	0.00143	CcSEcCtD
Ethosuximide—Dermatitis—Everolimus—kidney cancer	0.000269	0.00143	CcSEcCtD
Ethosuximide—Headache—Vinblastine—kidney cancer	0.000268	0.00143	CcSEcCtD
Ethosuximide—Headache—Everolimus—kidney cancer	0.000267	0.00142	CcSEcCtD
Ethosuximide—Abdominal pain—Dactinomycin—kidney cancer	0.000267	0.00142	CcSEcCtD
Ethosuximide—Asthenia—Sorafenib—kidney cancer	0.000266	0.00141	CcSEcCtD
Ethosuximide—Lethargy—Doxorubicin—kidney cancer	0.000263	0.0014	CcSEcCtD
Ethosuximide—Leukopenia—Paclitaxel—kidney cancer	0.000263	0.00139	CcSEcCtD
Ethosuximide—Hypersensitivity—Sunitinib—kidney cancer	0.000263	0.00139	CcSEcCtD
Ethosuximide—Decreased appetite—Vincristine—kidney cancer	0.000262	0.00139	CcSEcCtD
Ethosuximide—Vomiting—Erlotinib—kidney cancer	0.000262	0.00139	CcSEcCtD
Ethosuximide—Erythema multiforme—Capecitabine—kidney cancer	0.000261	0.00139	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Vincristine—kidney cancer	0.00026	0.00138	CcSEcCtD
Ethosuximide—Fatigue—Vincristine—kidney cancer	0.00026	0.00138	CcSEcCtD
Ethosuximide—Rash—Erlotinib—kidney cancer	0.00026	0.00138	CcSEcCtD
Ethosuximide—Dermatitis—Erlotinib—kidney cancer	0.000259	0.00138	CcSEcCtD
Ethosuximide—Eye disorder—Capecitabine—kidney cancer	0.000258	0.00137	CcSEcCtD
Ethosuximide—Headache—Erlotinib—kidney cancer	0.000258	0.00137	CcSEcCtD
Ethosuximide—Asthenia—Sunitinib—kidney cancer	0.000256	0.00136	CcSEcCtD
Ethosuximide—Nausea—Vinblastine—kidney cancer	0.000254	0.00135	CcSEcCtD
Ethosuximide—Somnolence—Gemcitabine—kidney cancer	0.000254	0.00135	CcSEcCtD
Ethosuximide—Nausea—Everolimus—kidney cancer	0.000253	0.00135	CcSEcCtD
Ethosuximide—Diarrhoea—Sorafenib—kidney cancer	0.000253	0.00135	CcSEcCtD
Ethosuximide—Immune system disorder—Capecitabine—kidney cancer	0.00025	0.00133	CcSEcCtD
Ethosuximide—Mediastinal disorder—Capecitabine—kidney cancer	0.000249	0.00132	CcSEcCtD
Ethosuximide—Decreased appetite—Gemcitabine—kidney cancer	0.000249	0.00132	CcSEcCtD
Ethosuximide—Hypersensitivity—Dactinomycin—kidney cancer	0.000249	0.00132	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000248	0.00132	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000247	0.00131	CcSEcCtD
Ethosuximide—Fatigue—Gemcitabine—kidney cancer	0.000246	0.00131	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Vincristine—kidney cancer	0.000246	0.00131	CcSEcCtD
Ethosuximide—Dizziness—Sorafenib—kidney cancer	0.000245	0.0013	CcSEcCtD
Ethosuximide—Nausea—Erlotinib—kidney cancer	0.000244	0.0013	CcSEcCtD
Ethosuximide—Diarrhoea—Sunitinib—kidney cancer	0.000244	0.0013	CcSEcCtD
Ethosuximide—Ataxia—Doxorubicin—kidney cancer	0.000242	0.00129	CcSEcCtD
Ethosuximide—Mental disorder—Capecitabine—kidney cancer	0.000242	0.00129	CcSEcCtD
Ethosuximide—Asthenia—Dactinomycin—kidney cancer	0.000242	0.00129	CcSEcCtD
Ethosuximide—Malnutrition—Capecitabine—kidney cancer	0.000241	0.00128	CcSEcCtD
Ethosuximide—Abdominal pain—Vincristine—kidney cancer	0.000238	0.00127	CcSEcCtD
Ethosuximide—Dizziness—Sunitinib—kidney cancer	0.000236	0.00125	CcSEcCtD
Ethosuximide—Vomiting—Sorafenib—kidney cancer	0.000235	0.00125	CcSEcCtD
Ethosuximide—Abdominal pain upper—Doxorubicin—kidney cancer	0.000235	0.00125	CcSEcCtD
Ethosuximide—Nervous system disorder—Paclitaxel—kidney cancer	0.000235	0.00125	CcSEcCtD
Ethosuximide—Rash—Sorafenib—kidney cancer	0.000233	0.00124	CcSEcCtD
Ethosuximide—Dermatitis—Sorafenib—kidney cancer	0.000233	0.00124	CcSEcCtD
Ethosuximide—Breast disorder—Doxorubicin—kidney cancer	0.000233	0.00124	CcSEcCtD
Ethosuximide—Skin disorder—Paclitaxel—kidney cancer	0.000233	0.00124	CcSEcCtD
Ethosuximide—Headache—Sorafenib—kidney cancer	0.000232	0.00123	CcSEcCtD
Ethosuximide—Muscle spasms—Capecitabine—kidney cancer	0.000231	0.00123	CcSEcCtD
Ethosuximide—Diarrhoea—Dactinomycin—kidney cancer	0.000231	0.00123	CcSEcCtD
Ethosuximide—Anorexia—Paclitaxel—kidney cancer	0.000228	0.00121	CcSEcCtD
Ethosuximide—Vomiting—Sunitinib—kidney cancer	0.000227	0.0012	CcSEcCtD
Ethosuximide—Rash—Sunitinib—kidney cancer	0.000225	0.00119	CcSEcCtD
Ethosuximide—Dermatitis—Sunitinib—kidney cancer	0.000224	0.00119	CcSEcCtD
Ethosuximide—Headache—Sunitinib—kidney cancer	0.000223	0.00119	CcSEcCtD
Ethosuximide—Hypersensitivity—Vincristine—kidney cancer	0.000222	0.00118	CcSEcCtD
Ethosuximide—Eosinophilia—Doxorubicin—kidney cancer	0.00022	0.00117	CcSEcCtD
Ethosuximide—Nausea—Sorafenib—kidney cancer	0.00022	0.00117	CcSEcCtD
Ethosuximide—Asthenia—Vincristine—kidney cancer	0.000216	0.00115	CcSEcCtD
Ethosuximide—Leukopenia—Capecitabine—kidney cancer	0.000215	0.00114	CcSEcCtD
Ethosuximide—Vomiting—Dactinomycin—kidney cancer	0.000214	0.00114	CcSEcCtD
Ethosuximide—Somnolence—Paclitaxel—kidney cancer	0.000213	0.00113	CcSEcCtD
Ethosuximide—Rash—Dactinomycin—kidney cancer	0.000213	0.00113	CcSEcCtD
Ethosuximide—Nausea—Sunitinib—kidney cancer	0.000212	0.00112	CcSEcCtD
Ethosuximide—Pancytopenia—Doxorubicin—kidney cancer	0.000211	0.00112	CcSEcCtD
Ethosuximide—Decreased appetite—Paclitaxel—kidney cancer	0.000208	0.00111	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000207	0.0011	CcSEcCtD
Ethosuximide—Fatigue—Paclitaxel—kidney cancer	0.000206	0.0011	CcSEcCtD
Ethosuximide—Diarrhoea—Vincristine—kidney cancer	0.000206	0.0011	CcSEcCtD
Ethosuximide—Asthenia—Gemcitabine—kidney cancer	0.000205	0.00109	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000203	0.00108	CcSEcCtD
Ethosuximide—Weight decreased—Doxorubicin—kidney cancer	0.000201	0.00107	CcSEcCtD
Ethosuximide—Nausea—Dactinomycin—kidney cancer	0.0002	0.00106	CcSEcCtD
Ethosuximide—Dizziness—Vincristine—kidney cancer	0.000199	0.00106	CcSEcCtD
Ethosuximide—Drowsiness—Doxorubicin—kidney cancer	0.000199	0.00105	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000197	0.00105	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000196	0.00104	CcSEcCtD
Ethosuximide—Diarrhoea—Gemcitabine—kidney cancer	0.000196	0.00104	CcSEcCtD
Ethosuximide—Nervous system disorder—Capecitabine—kidney cancer	0.000193	0.00102	CcSEcCtD
Ethosuximide—Vomiting—Vincristine—kidney cancer	0.000192	0.00102	CcSEcCtD
Ethosuximide—Skin disorder—Capecitabine—kidney cancer	0.000191	0.00101	CcSEcCtD
Ethosuximide—Urticaria—Paclitaxel—kidney cancer	0.00019	0.00101	CcSEcCtD
Ethosuximide—Rash—Vincristine—kidney cancer	0.00019	0.00101	CcSEcCtD
Ethosuximide—Dermatitis—Vincristine—kidney cancer	0.00019	0.00101	CcSEcCtD
Ethosuximide—Haematuria—Doxorubicin—kidney cancer	0.000189	0.00101	CcSEcCtD
Ethosuximide—Abdominal pain—Paclitaxel—kidney cancer	0.000189	0.00101	CcSEcCtD
Ethosuximide—Headache—Vincristine—kidney cancer	0.000189	0.001	CcSEcCtD
Ethosuximide—Anorexia—Capecitabine—kidney cancer	0.000187	0.000995	CcSEcCtD
Ethosuximide—Agranulocytosis—Doxorubicin—kidney cancer	0.000185	0.000984	CcSEcCtD
Ethosuximide—Vomiting—Gemcitabine—kidney cancer	0.000182	0.000966	CcSEcCtD
Ethosuximide—Rash—Gemcitabine—kidney cancer	0.00018	0.000958	CcSEcCtD
Ethosuximide—Dermatitis—Gemcitabine—kidney cancer	0.00018	0.000957	CcSEcCtD
Ethosuximide—Headache—Gemcitabine—kidney cancer	0.000179	0.000951	CcSEcCtD
Ethosuximide—Nausea—Vincristine—kidney cancer	0.000179	0.000951	CcSEcCtD
Ethosuximide—Hypersensitivity—Paclitaxel—kidney cancer	0.000176	0.000937	CcSEcCtD
Ethosuximide—Urinary tract disorder—Doxorubicin—kidney cancer	0.000176	0.000935	CcSEcCtD
Ethosuximide—Connective tissue disorder—Doxorubicin—kidney cancer	0.000175	0.00093	CcSEcCtD
Ethosuximide—Urethral disorder—Doxorubicin—kidney cancer	0.000175	0.000928	CcSEcCtD
Ethosuximide—Asthenia—Paclitaxel—kidney cancer	0.000172	0.000912	CcSEcCtD
Ethosuximide—Decreased appetite—Capecitabine—kidney cancer	0.000171	0.000907	CcSEcCtD
Ethosuximide—Nausea—Gemcitabine—kidney cancer	0.00017	0.000902	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00017	0.000901	CcSEcCtD
Ethosuximide—Fatigue—Capecitabine—kidney cancer	0.000169	0.0009	CcSEcCtD
Ethosuximide—Erythema multiforme—Doxorubicin—kidney cancer	0.000169	0.000895	CcSEcCtD
Ethosuximide—Eye disorder—Doxorubicin—kidney cancer	0.000167	0.000885	CcSEcCtD
Ethosuximide—Diarrhoea—Paclitaxel—kidney cancer	0.000164	0.00087	CcSEcCtD
Ethosuximide—Immune system disorder—Doxorubicin—kidney cancer	0.000161	0.000855	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Capecitabine—kidney cancer	0.000161	0.000853	CcSEcCtD
Ethosuximide—Mediastinal disorder—Doxorubicin—kidney cancer	0.000161	0.000853	CcSEcCtD
Ethosuximide—Dizziness—Paclitaxel—kidney cancer	0.000158	0.000841	CcSEcCtD
Ethosuximide—Mental disorder—Doxorubicin—kidney cancer	0.000156	0.00083	CcSEcCtD
Ethosuximide—Urticaria—Capecitabine—kidney cancer	0.000156	0.000829	CcSEcCtD
Ethosuximide—Abdominal pain—Capecitabine—kidney cancer	0.000155	0.000825	CcSEcCtD
Ethosuximide—Malnutrition—Doxorubicin—kidney cancer	0.000155	0.000824	CcSEcCtD
Ethosuximide—Vomiting—Paclitaxel—kidney cancer	0.000152	0.000809	CcSEcCtD
Ethosuximide—Rash—Paclitaxel—kidney cancer	0.000151	0.000802	CcSEcCtD
Ethosuximide—Dermatitis—Paclitaxel—kidney cancer	0.000151	0.000801	CcSEcCtD
Ethosuximide—Headache—Paclitaxel—kidney cancer	0.00015	0.000797	CcSEcCtD
Ethosuximide—Muscle spasms—Doxorubicin—kidney cancer	0.000149	0.000792	CcSEcCtD
Ethosuximide—Hypersensitivity—Capecitabine—kidney cancer	0.000145	0.000769	CcSEcCtD
Ethosuximide—Agitation—Doxorubicin—kidney cancer	0.000143	0.000757	CcSEcCtD
Ethosuximide—Nausea—Paclitaxel—kidney cancer	0.000142	0.000755	CcSEcCtD
Ethosuximide—Asthenia—Capecitabine—kidney cancer	0.000141	0.000749	CcSEcCtD
Ethosuximide—Leukopenia—Doxorubicin—kidney cancer	0.000139	0.000738	CcSEcCtD
Ethosuximide—Diarrhoea—Capecitabine—kidney cancer	0.000134	0.000714	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—POMC—kidney cancer	0.000131	0.00318	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000131	0.000697	CcSEcCtD
Ethosuximide—Dizziness—Capecitabine—kidney cancer	0.00013	0.00069	CcSEcCtD
Ethosuximide—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000128	0.00311	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000126	0.00306	CbGpPWpGaD
Ethosuximide—Vomiting—Capecitabine—kidney cancer	0.000125	0.000664	CcSEcCtD
Ethosuximide—Nervous system disorder—Doxorubicin—kidney cancer	0.000124	0.00066	CcSEcCtD
Ethosuximide—Rash—Capecitabine—kidney cancer	0.000124	0.000658	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—CCBL1—kidney cancer	0.000124	0.003	CbGpPWpGaD
Ethosuximide—Dermatitis—Capecitabine—kidney cancer	0.000124	0.000657	CcSEcCtD
Ethosuximide—Headache—Capecitabine—kidney cancer	0.000123	0.000654	CcSEcCtD
Ethosuximide—Skin disorder—Doxorubicin—kidney cancer	0.000123	0.000653	CcSEcCtD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000123	0.00298	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000123	0.00297	CbGpPWpGaD
Ethosuximide—Anorexia—Doxorubicin—kidney cancer	0.000121	0.000641	CcSEcCtD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000119	0.00289	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000119	0.00289	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000118	0.00285	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000118	0.00285	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—GSTT1—kidney cancer	0.000117	0.00285	CbGpPWpGaD
Ethosuximide—Nausea—Capecitabine—kidney cancer	0.000117	0.00062	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—PAK1—kidney cancer	0.000116	0.00281	CbGpPWpGaD
Ethosuximide—Somnolence—Doxorubicin—kidney cancer	0.000113	0.000598	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—PTGS1—kidney cancer	0.00011	0.00267	CbGpPWpGaD
Ethosuximide—Decreased appetite—Doxorubicin—kidney cancer	0.00011	0.000585	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000109	0.000581	CcSEcCtD
Ethosuximide—Fatigue—Doxorubicin—kidney cancer	0.000109	0.00058	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—PPAT—kidney cancer	0.000107	0.0026	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GLIPR1—kidney cancer	0.000107	0.0026	CbGpPWpGaD
Ethosuximide—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000104	0.00055	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—KDR—kidney cancer	0.000101	0.00245	CbGpPWpGaD
Ethosuximide—Urticaria—Doxorubicin—kidney cancer	0.000101	0.000534	CcSEcCtD
Ethosuximide—Abdominal pain—Doxorubicin—kidney cancer	0.0001	0.000532	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—APRT—kidney cancer	9.98e-05	0.00242	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—FH—kidney cancer	9.98e-05	0.00242	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.96e-05	0.00241	CbGpPWpGaD
Ethosuximide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	9.95e-05	0.00241	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MET—kidney cancer	9.91e-05	0.0024	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	9.67e-05	0.00234	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	9.65e-05	0.00234	CbGpPWpGaD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	9.47e-05	0.0023	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GPC3—kidney cancer	9.39e-05	0.00227	CbGpPWpGaD
Ethosuximide—Hypersensitivity—Doxorubicin—kidney cancer	9.33e-05	0.000496	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—CA2—kidney cancer	9.13e-05	0.00221	CbGpPWpGaD
Ethosuximide—Asthenia—Doxorubicin—kidney cancer	9.08e-05	0.000483	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—ALAD—kidney cancer	8.9e-05	0.00216	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.9e-05	0.00216	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.88e-05	0.00215	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ST3GAL2—kidney cancer	8.68e-05	0.0021	CbGpPWpGaD
Ethosuximide—Diarrhoea—Doxorubicin—kidney cancer	8.66e-05	0.00046	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTT1—kidney cancer	8.51e-05	0.00206	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTT1—kidney cancer	8.49e-05	0.00206	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ALDH1A1—kidney cancer	8.49e-05	0.00206	CbGpPWpGaD
Ethosuximide—Dizziness—Doxorubicin—kidney cancer	8.37e-05	0.000445	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTP1—kidney cancer	8.14e-05	0.00197	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—SLC5A3—kidney cancer	8.14e-05	0.00197	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PGK1—kidney cancer	8.14e-05	0.00197	CbGpPWpGaD
Ethosuximide—Vomiting—Doxorubicin—kidney cancer	8.05e-05	0.000428	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTP1—kidney cancer	8.03e-05	0.00195	CbGpPWpGaD
Ethosuximide—Rash—Doxorubicin—kidney cancer	7.98e-05	0.000424	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—LDHB—kidney cancer	7.98e-05	0.00193	CbGpPWpGaD
Ethosuximide—Dermatitis—Doxorubicin—kidney cancer	7.98e-05	0.000424	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—PTGS1—kidney cancer	7.97e-05	0.00193	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—PTGS1—kidney cancer	7.96e-05	0.00193	CbGpPWpGaD
Ethosuximide—Headache—Doxorubicin—kidney cancer	7.93e-05	0.000421	CcSEcCtD
Ethosuximide—Nausea—Doxorubicin—kidney cancer	7.52e-05	0.0004	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTM1—kidney cancer	7.48e-05	0.00181	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTM1—kidney cancer	7.38e-05	0.00179	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—RAF1—kidney cancer	7.32e-05	0.00177	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—ERBB2—kidney cancer	7.24e-05	0.00175	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—KDR—kidney cancer	7.22e-05	0.00175	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	7.21e-05	0.00175	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—kidney cancer	7.2e-05	0.00174	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—CYP1A1—kidney cancer	7.09e-05	0.00172	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MET—kidney cancer	7.07e-05	0.00171	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP1A1—kidney cancer	7e-05	0.0017	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	6.96e-05	0.00169	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CA9—kidney cancer	6.92e-05	0.00168	CbGpPWpGaD
Ethosuximide—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	6.85e-05	0.00166	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	6.72e-05	0.00163	CbGpPWpGaD
Ethosuximide—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—kidney cancer	6.57e-05	0.00159	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ACY1—kidney cancer	6.24e-05	0.00151	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—GSTP1—kidney cancer	5.9e-05	0.00143	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTP1—kidney cancer	5.89e-05	0.00143	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CRABP1—kidney cancer	5.88e-05	0.00143	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTP1—kidney cancer	5.82e-05	0.00141	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTP1—kidney cancer	5.8e-05	0.00141	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—VEGFA—kidney cancer	5.58e-05	0.00135	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	5.54e-05	0.00134	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ITPR2—kidney cancer	5.47e-05	0.00133	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	5.46e-05	0.00132	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—GSTM1—kidney cancer	5.42e-05	0.00131	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTM1—kidney cancer	5.41e-05	0.00131	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTM1—kidney cancer	5.35e-05	0.0013	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTM1—kidney cancer	5.33e-05	0.00129	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PDHB—kidney cancer	5.31e-05	0.00129	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—POMC—kidney cancer	5.29e-05	0.00128	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MAPK3—kidney cancer	5.28e-05	0.00128	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—RAF1—kidney cancer	5.22e-05	0.00127	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—RELA—kidney cancer	5.2e-05	0.00126	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—ERBB2—kidney cancer	5.17e-05	0.00125	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—CYP1A1—kidney cancer	5.14e-05	0.00125	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—CYP1A1—kidney cancer	5.13e-05	0.00124	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP1A1—kidney cancer	5.07e-05	0.00123	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP1A1—kidney cancer	5.06e-05	0.00123	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—MAPK1—kidney cancer	5.02e-05	0.00122	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CCBL1—kidney cancer	4.99e-05	0.00121	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ACHE—kidney cancer	4.99e-05	0.00121	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTT1—kidney cancer	4.99e-05	0.00121	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—KRAS—kidney cancer	4.74e-05	0.00115	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—SCARB1—kidney cancer	4.72e-05	0.00114	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PTGS1—kidney cancer	4.67e-05	0.00113	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PSMD7—kidney cancer	4.58e-05	0.00111	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—CTNNB1—kidney cancer	4.52e-05	0.0011	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ACY1—kidney cancer	4.52e-05	0.0011	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ACY1—kidney cancer	4.51e-05	0.00109	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	4.49e-05	0.00109	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—BCHE—kidney cancer	4.34e-05	0.00105	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GLIPR1—kidney cancer	4.32e-05	0.00105	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PPAT—kidney cancer	4.32e-05	0.00105	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—SLC5A5—kidney cancer	4.29e-05	0.00104	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—SLC2A1—kidney cancer	4.15e-05	0.001	CbGpPWpGaD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	4.13e-05	0.001	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—APRT—kidney cancer	4.02e-05	0.000974	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—FH—kidney cancer	4.02e-05	0.000974	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—VEGFA—kidney cancer	3.98e-05	0.000964	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTT1—kidney cancer	3.95e-05	0.000957	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PDHB—kidney cancer	3.84e-05	0.000931	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PDHB—kidney cancer	3.83e-05	0.000929	CbGpPWpGaD
Ethosuximide—CYP2E1—Biological oxidations—POMC—kidney cancer	3.83e-05	0.000928	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—POMC—kidney cancer	3.82e-05	0.000926	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GPC3—kidney cancer	3.78e-05	0.000916	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MAPK3—kidney cancer	3.76e-05	0.000912	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—PTGS1—kidney cancer	3.7e-05	0.000896	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CA2—kidney cancer	3.68e-05	0.000891	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CCBL1—kidney cancer	3.61e-05	0.000876	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CCBL1—kidney cancer	3.61e-05	0.000874	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ALAD—kidney cancer	3.58e-05	0.000868	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MAPK1—kidney cancer	3.58e-05	0.000868	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ST3GAL2—kidney cancer	3.5e-05	0.000848	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTP1—kidney cancer	3.46e-05	0.000838	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ALDH1A1—kidney cancer	3.42e-05	0.000828	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—KRAS—kidney cancer	3.38e-05	0.00082	CbGpPWpGaD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	3.35e-05	0.000811	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—SLC5A3—kidney cancer	3.28e-05	0.000794	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PGK1—kidney cancer	3.28e-05	0.000794	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—ABCB1—kidney cancer	3.27e-05	0.000793	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—LDHB—kidney cancer	3.21e-05	0.000779	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—GSTM1—kidney cancer	3.18e-05	0.00077	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GLIPR1—kidney cancer	3.13e-05	0.000759	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PPAT—kidney cancer	3.13e-05	0.000759	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PPAT—kidney cancer	3.13e-05	0.000758	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GLIPR1—kidney cancer	3.13e-05	0.000758	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CYP1A1—kidney cancer	3.01e-05	0.00073	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—FH—kidney cancer	2.91e-05	0.000706	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—APRT—kidney cancer	2.91e-05	0.000706	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—APRT—kidney cancer	2.91e-05	0.000704	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—FH—kidney cancer	2.91e-05	0.000704	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CA9—kidney cancer	2.79e-05	0.000675	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GPC3—kidney cancer	2.74e-05	0.000664	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.74e-05	0.000663	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GPC3—kidney cancer	2.73e-05	0.000662	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.7e-05	0.000654	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CA2—kidney cancer	2.66e-05	0.000645	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CA2—kidney cancer	2.66e-05	0.000644	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ALAD—kidney cancer	2.6e-05	0.000629	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ALAD—kidney cancer	2.59e-05	0.000628	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ST3GAL2—kidney cancer	2.53e-05	0.000614	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ST3GAL2—kidney cancer	2.53e-05	0.000613	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.51e-05	0.000609	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.48e-05	0.000601	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ALDH1A1—kidney cancer	2.48e-05	0.0006	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ALDH1A1—kidney cancer	2.47e-05	0.000599	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.38e-05	0.000578	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PGK1—kidney cancer	2.37e-05	0.000575	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—SLC5A3—kidney cancer	2.37e-05	0.000575	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CRABP1—kidney cancer	2.37e-05	0.000574	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PGK1—kidney cancer	2.37e-05	0.000574	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—SLC5A3—kidney cancer	2.37e-05	0.000574	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.35e-05	0.00057	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—LDHB—kidney cancer	2.33e-05	0.000564	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—LDHB—kidney cancer	2.32e-05	0.000563	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—POMC—kidney cancer	2.25e-05	0.000544	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ITPR2—kidney cancer	2.2e-05	0.000534	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ACY1—kidney cancer	2.1e-05	0.000508	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CA9—kidney cancer	2.02e-05	0.000489	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CA9—kidney cancer	2.01e-05	0.000488	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ACHE—kidney cancer	2.01e-05	0.000487	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTT1—kidney cancer	2.01e-05	0.000487	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—SCARB1—kidney cancer	1.9e-05	0.000461	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PTGS1—kidney cancer	1.88e-05	0.000456	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PSMD7—kidney cancer	1.85e-05	0.000447	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PTGS2—kidney cancer	1.79e-05	0.000434	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PDHB—kidney cancer	1.78e-05	0.000432	CbGpPWpGaD
Ethosuximide—CYP3A4—Biological oxidations—POMC—kidney cancer	1.78e-05	0.000431	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—BCHE—kidney cancer	1.75e-05	0.000424	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—SLC5A5—kidney cancer	1.73e-05	0.000419	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CRABP1—kidney cancer	1.72e-05	0.000416	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CRABP1—kidney cancer	1.71e-05	0.000415	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CCBL1—kidney cancer	1.68e-05	0.000406	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—SLC2A1—kidney cancer	1.67e-05	0.000405	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ITPR2—kidney cancer	1.6e-05	0.000387	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ITPR2—kidney cancer	1.59e-05	0.000386	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PTEN—kidney cancer	1.56e-05	0.000379	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTT1—kidney cancer	1.46e-05	0.000353	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ACHE—kidney cancer	1.46e-05	0.000353	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PPAT—kidney cancer	1.45e-05	0.000352	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.45e-05	0.000352	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTT1—kidney cancer	1.45e-05	0.000352	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ACHE—kidney cancer	1.45e-05	0.000352	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTP1—kidney cancer	1.39e-05	0.000337	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—SCARB1—kidney cancer	1.38e-05	0.000334	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—SCARB1—kidney cancer	1.37e-05	0.000333	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PTGS1—kidney cancer	1.36e-05	0.00033	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PTGS1—kidney cancer	1.36e-05	0.00033	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—APRT—kidney cancer	1.35e-05	0.000327	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—FH—kidney cancer	1.35e-05	0.000327	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PSMD7—kidney cancer	1.34e-05	0.000324	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PSMD7—kidney cancer	1.33e-05	0.000323	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ABCB1—kidney cancer	1.32e-05	0.000319	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTM1—kidney cancer	1.28e-05	0.00031	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GPC3—kidney cancer	1.27e-05	0.000308	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—BCHE—kidney cancer	1.27e-05	0.000307	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—BCHE—kidney cancer	1.27e-05	0.000307	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—SLC5A5—kidney cancer	1.25e-05	0.000303	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—SLC5A5—kidney cancer	1.25e-05	0.000303	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CA2—kidney cancer	1.24e-05	0.000299	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP1A1—kidney cancer	1.21e-05	0.000294	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—SLC2A1—kidney cancer	1.21e-05	0.000293	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—SLC2A1—kidney cancer	1.21e-05	0.000292	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ALAD—kidney cancer	1.2e-05	0.000292	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.18e-05	0.000285	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.15e-05	0.000278	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PIK3CA—kidney cancer	1.1e-05	0.000267	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PGK1—kidney cancer	1.1e-05	0.000267	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.1e-05	0.000267	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—LDHB—kidney cancer	1.08e-05	0.000262	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTP1—kidney cancer	1.01e-05	0.000244	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTP1—kidney cancer	1.01e-05	0.000244	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ABCB1—kidney cancer	9.55e-06	0.000231	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ABCB1—kidney cancer	9.53e-06	0.000231	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CA9—kidney cancer	9.37e-06	0.000227	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTM1—kidney cancer	9.27e-06	0.000225	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTM1—kidney cancer	9.25e-06	0.000224	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—POMC—kidney cancer	9.04e-06	0.000219	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP1A1—kidney cancer	8.79e-06	0.000213	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP1A1—kidney cancer	8.77e-06	0.000212	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CRABP1—kidney cancer	7.96e-06	0.000193	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ITPR2—kidney cancer	7.4e-06	0.000179	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PTGS2—kidney cancer	7.21e-06	0.000175	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ACHE—kidney cancer	6.75e-06	0.000164	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTT1—kidney cancer	6.75e-06	0.000164	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—POMC—kidney cancer	6.55e-06	0.000159	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—POMC—kidney cancer	6.54e-06	0.000158	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—SCARB1—kidney cancer	6.39e-06	0.000155	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PTGS1—kidney cancer	6.33e-06	0.000153	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PTEN—kidney cancer	6.29e-06	0.000152	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PSMD7—kidney cancer	6.2e-06	0.00015	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—BCHE—kidney cancer	5.88e-06	0.000143	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—SLC5A5—kidney cancer	5.81e-06	0.000141	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—SLC2A1—kidney cancer	5.61e-06	0.000136	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PTGS2—kidney cancer	5.23e-06	0.000127	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PTGS2—kidney cancer	5.21e-06	0.000126	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTP1—kidney cancer	4.68e-06	0.000113	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PTEN—kidney cancer	4.56e-06	0.00011	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PTEN—kidney cancer	4.55e-06	0.00011	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PIK3CA—kidney cancer	4.44e-06	0.000108	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ABCB1—kidney cancer	4.43e-06	0.000107	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTM1—kidney cancer	4.3e-06	0.000104	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.08e-06	9.88e-05	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PIK3CA—kidney cancer	3.21e-06	7.79e-05	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PIK3CA—kidney cancer	3.21e-06	7.77e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—POMC—kidney cancer	3.04e-06	7.37e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PTGS2—kidney cancer	2.42e-06	5.87e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PTEN—kidney cancer	2.11e-06	5.12e-05	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.49e-06	3.61e-05	CbGpPWpGaD
